At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET
Xenon Pharmaceuticals closed a public offering of 12,236,843 common shares and pre-funded warrants to purchase 877,194 additional shares, raising approximately $747.5 million in gross proceeds. The offering was priced at $57.00 per common share, with pre-funded warrants sold at $56.9999 and an exercise price of $0.0001 per warrant.
- Xenon raised approximately $747.5 million in gross proceeds from the offering.
- The offering included 12,236,843 common shares and pre-funded warrants for 877,194 additional shares.
- Common shares were priced at $57.00; pre-funded warrants were priced at $56.9999 with a nominal exercise price of $0.0001.
- The underwriters' option to purchase additional shares was fully exercised.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access